Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents
From MaRDI portal
Publication:6642051
DOI10.1111/RSSC.12294MaRDI QIDQ6642051
Publication date: 21 November 2024
Published in: Journal of the Royal Statistical Society. Series C. Applied Statistics (Search for Journal in Brave)
cubic splinesmaximum tolerated dosedrug combinationescalation with overdose controlBayesian adaptive designcancer phase I--II trials
Related Items (2)
A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages ⋮ A nonparametric Bayesian method for dose finding in drug combinations cancer trials
This page was built for publication: Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6642051)
